Dr. Alvin Wells, Rheumatologist

Paid consultant to GSK at the time of filming.


    DR WELLS: Hi, I’m Doctor Alvin Wells, a board-certified rheumatologist practicing in Franklin, Wisconsin.

    ON-SCREEN TEXT: Dr. Alvin Wells, Rheumatologist
    Paid consultant to GSK at the time of filming.


    DR WELLS: Many of my rheumatology colleagues ask me all the time, “Why BENLYSTA?” I always tell them to take a step back and think about where we are in treating any patient in medicine now. We should be trying to use, to the best of our ability, evidence-based medicine.

    ON-SCREEN TEXT: “Evidence-based medicine”

    DR WELLS: And what does “evidence-based medicine” look like? It means that we have taken clinical trial data from randomized, placebo-controlled trials, data from peer-reviewed journals, and data that has been approved by the FDA to treat our patients. And fast forward, that’s where we are in using BENLYSTA in our patients with lupus.

    ON-SCREEN TEXT: “Approved by the FDA”

    DR WELLS: I also remind them and say when BENLYSTA was approved, we hadn’t had a drug for a number of years in treating patients with lupus. Before this, we had had drugs we kind of had borrowed and stolen from other specialties like oncology, drugs that go back into the 50s and into the 60s.

    DR WELLS: So, when BENLYSTA came out, and remember this drug was designed to treat lupus, and targeting the underlying disease activity, the mechanism of action really kind of drives home that and that improvement that we see in our patients.

    ON-SCREEN TEXT: BENLYSTA targets underlying disease activity

    DR WELLS: So overall we talk about BENLYSTA, a drug that is designed specifically for disease activity in patients with lupus, a drug that has been FDA approved, that has a wealth of data around it, BENLYSTA has been a significant component of my armamentarium in treating patients with lupus disease activity.

    ON-SCREEN TEXT: “BENLYSTA has been a significant component of my armamentarium”

    DR WELLS: Thank you for watching. Visit the BENLYSTA website for more information.

    BENLYSTA is indicated for patients aged ≥5 with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard therapy and patients aged ≥18 with active lupus nephritis receiving standard therapy. BENLYSTA is not recommended in patients with severe active central nervous system lupus or in combination with other biologics.



    Previous anaphylaxis with BENLYSTA.


    Serious Infections: Serious and sometimes fatal infections have been reported and occurred more frequently with BENLYSTA. Use caution in patients with severe or chronic infections, and consider interrupting therapy in patients with a new infection.

    Progressive Multifocal Leukoencephalopathy (PML): Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported. If PML is confirmed, consider stopping immunosuppressant therapy, including BENLYSTA.

    Please see additional Important Safety Information and full Prescribing Information, including Medication Guide, on the BENLYSTAHCP.com website.

    Intravenous Use 120 mg/vial
    Subcutaneous Use 200 mg/mL

    GSK Logo

    Trademarks are owned by or licensed to the GSK group of companies. | ©2021 GSK or licensor. BELVID210052 November 2021. Produced in USA.

You may also like


Dr. Grace Wright, Rheumatologist


Dr. William Pendergraft, Nephrologist

Paid consultants to GSK at the time of filming.